BioNexus Gene Lab Corp
For the period ended Jun 30, 2026. Filed Aug 14, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 14, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 1. Legal Proceedings
Except as described below, the Company is not a party to any material pending legal proceeding, and no such proceeding is known by the Company to be threatened or contemplated.
As previously disclosed, on May 13, 2026, the Company issued Letters of Demand to the five former officers and directors of Chemrex demanding that the former officers and directors repay to Chemrex the collective sum of approximately $2,944,000 within 14 days. Based on its ongoing investigation, the Company alleges that the former officers and directors caused these amounts to be paid from Chemrex’s corporate accounts during the period from July 2024 through August 2025. The Company alleges that the transactions were unauthorized under Malaysian law; these allegations have not been adjudicated by a court or tribunal. The Company continues to investigate the activities of these parties and their effect on Chemrex. The Company intends to pursue available claims and remedies, as appropriate. As of the date of this report, no court or tribunal proceeding has been commenced in connection with the Letters of Demand.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.